Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
International MS Journal|November 15, 2006
Editorial: the pitfalls of combination therapyPatrick Vermersch
Neurodegenerative Disease Management|December 23, 2014
MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU studyPatrick Vermersch
Presse Medicale (Paris, France : 1983)|March 19, 2004
[Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?]Patrick Vermersch
Expert Review of Neurotherapeutics|April 1, 2011
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical dataPatrick Vermersch
Neurodegenerative Disease Management|November 28, 2015
Advances in the management of MS symptoms: recently proposed clinical management algorithmsPatrick Vermersch
Journal of the Neurological Sciences|January 25, 2014
From the fundamentals of multiple sclerosis to clinical managementOscar Fernández, Patrick Vermersch
Expert Review of Neurotherapeutics|February 2, 2013
Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionalsNicolas Collongues, Patrick Vermersch
European Neurology|October 13, 2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily PracticePatrick Vermersch, Maria Trojano
Neurology|December 15, 2004
Concomitant therapy for multiple sclerosisWilliam H Stuart, Patrick Vermersch
Current Medical Research and Opinion|September 21, 2007
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulationThomas P Leist, Patrick Vermersch
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
International MS Journal|November 15, 2006
Editorial: the pitfalls of combination therapyPatrick Vermersch
Neurodegenerative Disease Management|December 23, 2014
MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU studyPatrick Vermersch
Presse Medicale (Paris, France : 1983)|March 19, 2004
[Are there arguments for initiating an etiological treatment at the onset of the first demyelinating episode?]Patrick Vermersch
Expert Review of Neurotherapeutics|April 1, 2011
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical dataPatrick Vermersch
Neurodegenerative Disease Management|November 28, 2015
Advances in the management of MS symptoms: recently proposed clinical management algorithmsPatrick Vermersch
Journal of the Neurological Sciences|January 25, 2014
From the fundamentals of multiple sclerosis to clinical managementOscar Fernández, Patrick Vermersch
Expert Review of Neurotherapeutics|February 2, 2013
Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionalsNicolas Collongues, Patrick Vermersch
European Neurology|October 13, 2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily PracticePatrick Vermersch, Maria Trojano
Neurology|December 15, 2004
Concomitant therapy for multiple sclerosisWilliam H Stuart, Patrick Vermersch
Current Medical Research and Opinion|September 21, 2007
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulationThomas P Leist, Patrick Vermersch
Pageof 25